Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov-Dec;30(6):879-85.
doi: 10.1016/j.urolonc.2010.08.005. Epub 2010 Oct 8.

Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience

Affiliations

Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience

Alan J Rodney et al. Urol Oncol. 2012 Nov-Dec.

Abstract

Objective: Primary mediastinal germ-cell tumors are rare, and the effect of newer drugs and treatment strategies in this disease on overall survival is not known. We retrospectively assessed treatment outcomes at a single institution.

Materials and methods: We identified men seen at our institution from 1998 through 2005 for mediastinal germ-cell tumors. Medical records were reviewed for patient characteristics, histology, tumor markers, treatment, and survival outcome.

Results: Thirty-four patients met study criteria, of whom 27 had nonseminomatous germ-cell tumor (NSGCT) and 7 had pure seminoma. Eleven patients (41%) with NSGCT were alive at last contact with a median overall survival time of 33.5 months. Among 13 patients with NSGCT referred to us at initial diagnosis, 7 (54%) were alive and recurrence-free at a median follow-up of 56.5 months. Progression-free survival was associated with absence of risk factors (any histology other than endodermal sinus tumor, β-hCG > 1000 mIU/mL, or disease outside the mediastinum). For the patients whose disease progressed (n = 5) or who had been referred to us for salvage treatment (n = 14), the 3-year overall survival from the date of first progression was 23%. Conversely, patients with seminoma did uniformly well with platinum-based chemotherapy; most did not undergo radiation or surgery.

Conclusion: Chemotherapy given to maximum effect followed by surgical consolidation resulted in long-term progression-free survival for 54% of patients with mediastinal NSGCT. The number of risk factors present at diagnosis may be associated with survival outcome and should be studied in a larger test group.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier plot of the (A) overall survival and (B) progression-free survival duration for 27 patients with mediastinal nonseminomatous germ-cell tumors. The median progression-free survival from diagnosis was 8.5 months for patients referred in relapse and was not estimable for the patients referred at diagnosis (log rank P < 0.001).
Fig. 2
Fig. 2
Kaplan-Meier plot of the overall survival duration for 19 patients with relapsed mediastinal nonseminomatous germ-cell tumors. Survival time was calculated from the date of first progression.

References

    1. Moran CA, Suster S. Primary germ-cell tumors of the mediastinum: I Analysis of 322 cases with special emphasis on teratomatous lesions and a proposal for histopathologic classification and clinical staging. Cancer. 1997;80:681–90. - PubMed
    1. Moran CA, Suster S, Przygodzki RM, et al. Primary germ-cell tumors of the mediastinum: II Mediastinal seminomas—a clinicopathologic and immunohistochemical study of 120 cases. Cancer. 1997;80:691–8. - PubMed
    1. Moran CA, Suster S, Koss MN. Primary germ-cell tumors of the mediastinum: III Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ-cell tumors of the mediastinum—a clinicopathologic and immunohistochemical study of 64 cases. Cancer. 1997;80:699–707. - PubMed
    1. International Germ-cell Consensus Classification: A prognostic factor-based staging system for metastatic germ-cell cancers International Germ-cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594–603. - PubMed
    1. Logothetis CJ, Samuels ML, Selig DE, et al. Chemotherapy of extragonadal germ-cell tumors. J Clin Oncol. 1985;3:316–25. - PubMed

Publication types